Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $26.5 million.

  • IDEAYA Biosciences' Other Accumulated Expenses rose 3283.22% to $26.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $26.5 million, marking a year-over-year increase of 3283.22%. This contributed to the annual value of $26.5 million for FY2025, which is 3283.22% up from last year.
  • Latest data reveals that IDEAYA Biosciences reported Other Accumulated Expenses of $26.5 million as of Q4 2025, which was up 3283.22% from $32.9 million recorded in Q3 2025.
  • IDEAYA Biosciences' 5-year Other Accumulated Expenses high stood at $32.9 million for Q3 2025, and its period low was $5.0 million during Q1 2021.
  • For the 5-year period, IDEAYA Biosciences' Other Accumulated Expenses averaged around $14.6 million, with its median value being $11.2 million (2022).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 17225.73% in 2021, then plummeted by 2440.5% in 2023.
  • IDEAYA Biosciences' Other Accumulated Expenses (Quarter) stood at $7.9 million in 2021, then soared by 41.73% to $11.1 million in 2022, then dropped by 4.22% to $10.7 million in 2023, then surged by 86.92% to $20.0 million in 2024, then soared by 32.83% to $26.5 million in 2025.
  • Its last three reported values are $26.5 million in Q4 2025, $32.9 million for Q3 2025, and $28.1 million during Q2 2025.